News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
279,950 Results
Type
Article (14807)
Company Profile (300)
Press Release (264839)
Multimedia
Podcasts (73)
Webinars (11)
Section
Business (79789)
Career Advice (159)
Deals (13315)
Drug Delivery (40)
Drug Development (50667)
Employer Resources (31)
FDA (5823)
Job Trends (5163)
News (144986)
Policy (10067)
Tag
Academia (918)
Accelerated approval (18)
Adcomms (14)
Allergies (76)
Alliances (21763)
ALS (119)
Alzheimer's disease (1015)
Antibody-drug conjugate (ADC) (217)
Approvals (6000)
Artificial intelligence (235)
Autoimmune disease (93)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (98)
Biotechnology (230)
Bladder cancer (94)
Brain cancer (42)
Breast cancer (322)
Cancer (2935)
Cardiovascular disease (225)
Career advice (145)
Career pathing (6)
CAR-T (210)
CDC (5)
Cell therapy (540)
Cervical cancer (14)
Clinical research (43387)
Collaboration (1021)
Company closure (2)
Compensation (547)
Complete response letters (35)
COVID-19 (1093)
CRISPR (81)
C-suite (477)
Cystic fibrosis (107)
Data (4062)
Denatured (13)
Depression (80)
Diabetes (239)
Diagnostics (1365)
Digital health (9)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (170)
Drug pricing (42)
Drug shortages (3)
Duchenne muscular dystrophy (202)
Earnings (31539)
Editorial (23)
Employer branding (4)
Employer resources (29)
Events (51346)
Executive appointments (608)
FDA (7420)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (6)
Frontotemporal dementia (19)
Funding (905)
Gene editing (169)
Generative AI (18)
Gene therapy (457)
GLP-1 (487)
Government (1139)
Grass and pollen (3)
Guidances (162)
Healthcare (6607)
HIV (15)
Huntington's disease (38)
IgA nephropathy (69)
Immunology and inflammation (177)
Immuno-oncology (27)
Indications (50)
Infectious disease (1191)
Inflammatory bowel disease (150)
Inflation Reduction Act (10)
Influenza (35)
Intellectual property (153)
Interviews (18)
IPO (7333)
IRA (12)
Job creations (867)
Job search strategy (129)
Kidney cancer (9)
Labor market (22)
Layoffs (241)
Leadership (9)
Legal (1399)
Liver cancer (39)
Longevity (9)
Lung cancer (405)
Lymphoma (240)
Machine learning (21)
Management (7)
Manufacturing (338)
MASH (127)
Medical device (2656)
Medtech (2663)
Mergers & acquisitions (6558)
Metabolic disorders (672)
Multiple sclerosis (92)
NASH (13)
Neurodegenerative disease (206)
Neuropsychiatric disorders (63)
Neuroscience (1854)
NextGen: Class of 2025 (2030)
Non-profit (860)
Now hiring (28)
Obesity (298)
Opinion (122)
Ovarian cancer (122)
Pain (91)
Pancreatic cancer (143)
Parkinson's disease (210)
Partnered (12)
Patents (280)
Patient recruitment (286)
Peanut (42)
People (26493)
Pharmaceutical (45)
Pharmacy benefit managers (6)
Phase I (15358)
Phase II (20161)
Phase III (12750)
Pipeline (2593)
Policy (86)
Postmarket research (853)
Preclinical (6515)
Press Release (30)
Prostate cancer (137)
Psychedelics (48)
Radiopharmaceuticals (231)
Rare diseases (581)
Real estate (1446)
Recruiting (12)
Regulatory (9693)
Reports (19)
Research institute (968)
Resumes & cover letters (18)
Rett syndrome (21)
RNA editing (16)
RSV (16)
Schizophrenia (118)
Series A (169)
Series B (121)
Service/supplier (1)
Sickle cell disease (75)
Special edition (17)
Spinal muscular atrophy (118)
Sponsored (15)
Startups (2000)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (17)
The Weekly (59)
Vaccines (318)
Venture capital (58)
Weight loss (161)
Women's health (23)
Worklife (2)
Date
Today (16)
Last 7 days (74)
Last 30 days (959)
Last 365 days (18079)
2026 (33)
2025 (18098)
2024 (20548)
2023 (22415)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (153)
Alabama (63)
Alaska (2)
Arizona (66)
Arkansas (5)
Asia (18140)
Australia (3083)
California (6678)
Canada (1769)
China (715)
Colorado (231)
Connecticut (237)
Delaware (220)
Europe (38912)
Florida (840)
Georgia (202)
Hawaii (2)
Idaho (17)
Illinois (367)
India (31)
Indiana (151)
Iowa (8)
Japan (204)
Kansas (79)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (708)
Massachusetts (5277)
Michigan (103)
Minnesota (238)
Mississippi (3)
Missouri (31)
Montana (15)
Nebraska (5)
Nevada (29)
New Hampshire (18)
New Jersey (1568)
New Mexico (12)
New York (1673)
North Carolina (788)
North Dakota (6)
Northern California (3244)
Ohio (171)
Oklahoma (11)
Oregon (22)
Pennsylvania (1212)
Puerto Rico (8)
Rhode Island (25)
South America (210)
South Carolina (9)
Southern California (2634)
Tennessee (37)
Texas (861)
United States (22104)
Utah (92)
Virginia (130)
Washington D.C. (36)
Washington State (560)
West Virginia (1)
Wisconsin (35)
279,950 Results for "cerevel therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Acquisitions
Unswayed by Cerevel Failure, AbbVie Buys Gilgamesh’s Depression Drug for $1.2B
The deal extends AbbVie’s commitment to the psychedelics space and depression, after emraclidine’s high-profile flop in schizophrenia last November.
August 25, 2025
·
3 min read
·
Annalee Armstrong
Parkinson’s disease
A Month After Stunning Schizophrenia Fail, AbbVie’s Other Cerevel Asset Shines Again
Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie announced the Phase II failure of another key Cerevel asset, emraclidine.
December 9, 2024
·
1 min read
·
Annalee Armstrong
Deals
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease (PD), and mood disorders.
December 6, 2023
·
11 min read
Genetown
Cerevel Therapeutics to Present at Upcoming November 2023 Investor Conferences
Cerevel Therapeutics announced that members of the management team will participate in two upcoming investor conferences during the month of November.
November 8, 2023
·
4 min read
Press Releases
AbbVie Completes Acquisition of Cerevel Therapeutics
August 1, 2024
·
7 min read
Genetown
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease
Cerevel Therapeutics announced it will host a tavapadon investor webcast on Monday, December 11, from 10:00 to 11:30 a.m. ET.
November 29, 2023
·
5 min read
Drug Development
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Cerevel Therapeutics announced positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon, the first and only D1/D5 receptor partial agonist being studied as a once-daily treatment for Parkinson’s disease.
April 18, 2024
·
11 min read
Drug Development
Cerevel Gets Phase III Parkinson’s Win on Heels of $8.7B AbbVie Acquisition
Cerevel Therapeutics on Thursday reported positive data from its Phase III TEMPO-3 trial, showing that tavapadon can significantly improve symptom control in patients with Parkinson’s disease.
April 18, 2024
·
2 min read
·
Tristan Manalac
Business
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, reported financial results for the third quarter ended September 30, 2023 and provided key pipeline and business updates.
November 1, 2023
·
12 min read
Genetown
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock - October 11, 2023
Cerevel Therapeutics Holdings, Inc., a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock.
October 11, 2023
·
5 min read
1 of 27,995
Next
